Activating mutations in six positive regulators and inactivating mutations in five negative regulators of the NFKB pathway have been identified in 20% of untreated MM tumors and 45% of multiple myeloma cell lines (MMCLs), rendering the cells less dependent on ligand mediated NFKB activation. The gene discussed is NFKB1; the disease is plasma cell myeloma.